ATI INC

ATI

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Driehaus Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 213,111Value: $24.5M

# Signal Note: Driehaus Capital Initiates ATI Position Driehaus Capital's $24.5M entry into ATI Therapeutics signals conviction in the company's pipeline, likely driven by phase progression catalysts in its lead programs (ATI-2173 for HBV and ATI-1801 for RSV). The position size represents meaningful capital deployment for a growth-focused biotech allocator, suggesting either upcoming data readouts or competitive differentiation in antiviral therapeutics that justify conviction at current valuation levels.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN1 fund WLDN1 fund LASR1 fund ONTO1 fund VALE1 fund TNDM1 fund TKO1 fund TNL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: